Table 1.
Baseline characteristics of older women with adjudicated CHD during participation in the Women’s Health Initiative Hormone and Diet Modification Trials
| All N=2627 N (%) |
E+P N=659 (25%) N (%) |
E-Alone N=528 (20%) N (%) |
Diet only N=1440 (55%) N (%) |
p-value | ||
|---|---|---|---|---|---|---|
| Age | 50–59 | 494 (19) | 128 (19) | 90 (17) | 276(19) | 0.60 |
| 60–69 | 1283 (49) | 317 (48) | 254 (48) | 712 (49) | ||
| 70–79 | 850 (32) | 214 (32) | 184 (35) | 452 (31) | ||
| Region | Midwest | 621 (24) | 181 (27) | 140 (27) | 300 (21) | <0.0001 |
| Northeast | 652 (25) | 156 (24) | 110 (21) | 386 (27) | ||
| South | 710 (27) | 171 (26) | 168 (32) | 371 (26) | ||
| West | 644 (25) | 151 (23) | 110 (21) | 383 (27) | ||
| Race/ethnicity | American Indian | 10 (0.4) | 1 (0.1) | 3 (1) | 6 (0.4) | <0.0001 |
| Asian/Pacific Islander | 33(1) | 10 (2) | 5 (1) | 18 (1) | ||
| Black | 228 (9) | 40 (6) | 58 (11) | 130 (9) | ||
| Hispanic | 71 (3) | 26 (4) | 24 (5) | 21 (1) | ||
| White | 2248 (86) | 568 (86) | 431 (82) | 1249 (87) | ||
| Unknown | 37 (1) | 14 (2) | 7 (1) | 16 (1) | ||
| Stroke | 59 (2) | 12 (2) | 18 (3) | 29 (2) | 0.13 | |
| Peripheral arterial disease | 75 (3) | 17 (3) | 17 (3) | 41 (3) | 0.80 | |
| Diabetes | 439 (17) | 110 (17) | 114 (22) | 215 (15) | 0.002 | |
| Hypertension | Yes - treated | 957 (42) | 206 (35) | 190 (41) | 561 (45) | 0.002 |
| Yes - untreated | 221 (10) | 68 (12) | 50 (11) | 103 (8) | ||
| Smoking | Current | 304 (12) | 96 (15) | 88 (17) | 120 (8) | <0.0001 |
| Never | 1240 (48) | 290 (45) | 262 (50) | 688 (48) | ||
| Past | 1047 (40) | 261 (40) | 172 (33) | 614 (43) | ||
| BMI | <25 | 552 (21) | 164 (25) | 102 (19) | 286 (20) | 0.08 |
| 25–<30 | 951 (36) | 234 (36) | 192 (36) | 525 (37) | ||
| ≥30 | 1120 (43) | 261 (40) | 234 (44) | 625 (44) | ||
| Insurance coverage | 2481 (95) | 611 (93) | 479 (93) | 1391 (97) | <0.0001 | |
| Doctor visit in past year | 2106 (83) | 509 (79) | 396 (79) | 1201 (86) | <0.0001 | |
| Income | <$10,000 | 144 (6) | 27 (4) | 55 (11) | 62 (6) | <0.0001 |
| $10,000–<20,000 | 528 (21) | 149 (24) | 146 (29) | 233 (17) | ||
| $20,000–<35,000 | 728 (29) | 197 (32) | 134 (26) | 397 (29) | ||
| $35,000–<50,000 | 500 (20) | 112 (18) | 82 (16) | 306 (22) | ||
| $50,000–<75,000 | 376 (15) | 86 (14) | 69 (14) | 221 (16) | ||
| ≥$75,000 | 213 (9) | 50 (8) | 20 (4) | 143 (11) | ||
| Number of medications | 0 | 341 (13) | 124 (19) | 75 (14) | 142 (10) | <0.0001 |
| 1 | 419 (16) | 122 (19) | 93 (18) | 204 (14) | ||
| 2 | 470 (18) | 127 (19) | 103 (20) | 240 (17) | ||
| 3 | 378 (14) | 91 (14) | 70 (13) | 217 (15) | ||
| 4 | 355 (14) | 82 (12) | 68 (13) | 205 (14) | ||
| 5 | 230 (9) | 42 (6) | 43 (8) | 145 (10) | ||
| 6–7 | 261 (10) | 43 (7) | 48 (9) | 170 (12) | ||
| ≥8 | 173 (7) | 28 (4) | 28 (5) | 117 (8) |
E+P = Estrogen plus Progestin trial
E-Alone = Estrogen only trial